New TMF Maturity Model from Veeva Systems Offers Expert Guidance on Developing and Executing a Strategy to Improve TMF Business Operations
Consultative service, online or in-person, provides life sciences organizations with TMF roadmap
PLEASANTON, CA – Jan. 21, 2016– Veeva Systems introduces the
The Veeva TMF Maturity Model assessment provides companies with a tailored report, outlining the current state of their TMF, comparison to industry benchmarks, and a roadmap for improvement. More than 60 life sciences companies have already completed the evaluation.
Data amassed to date shows companies who have completed the Veeva TMF Maturity Model evaluation are only halfway along the full TMF maturity curve, averaging 2.54 on a scale of one to five. These empirical findings are consistent with industry-wide survey data from the annual
“In just one year, the industry has seen a dramatic uptick in electronic TMF application adoption,” said Jason Methia, director of Vault eTMF strategy at Veeva. “The Veeva TMF Maturity Model provides the industry with a reliable framework to make systematic strides towards shedding paper and transitioning toward automated methods and systems.” Kathryn King, vice president of Vault Clinical at Veeva, will discuss how to move along the TMF continuum during ExL Pharma’s 5th Trial Master File Summit, at 10:45 AM on January 21, 2016 at the Westin Arlington Gateway in Virginia.
Life sciences organizations can visit
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025